Biomarker studies are increasingly expected to generate deeper biological insight from limited material. Longitudinal studies, archived specimens, rare-disease cohorts and difficult-to-collect biofluids can all restrict the sample volume available for analysis.

Historically, limited volume often meant limiting the number of biomarkers that could be measured. Advances in ultra-sensitive, multiplex proteomics are changing this. Researchers can now generate broad protein profiles from microlitre-scale samples while preserving valuable material for repeat analysis, complementary testing or targeted validation.

The aim is not simply to use the smallest possible volume. A successful low-volume workflow must generate reliable, reproducible and biologically meaningful data from every available sample.

What is a low-volume biomarker workflow?

A low-volume workflow is an analytical strategy designed to minimise sample consumption while still meeting the scientific and technical requirements of the study.

This can be particularly valuable when working with:

• Longitudinal clinical samples

• Cerebrospinal fluid and other difficult-to-collect biofluids

• Biobank specimens with limited remaining volume

• Studies involving rare-disease, paediatric or otherwise sample-limited cohorts

• Samples that need to support several analytical methods

Low-volume analysis involves more than reducing assay input. It requires careful decisions about sample allocation, target selection, assay sensitivity and how much material should be retained for quality control, repeat testing or future validation.

What can low-volume workflows enable?

• More informative longitudinal studies

Many biomarkers are dynamic rather than fixed. Inflammatory proteins, neurological markers and indicators of treatment response may change over hours, days or months.

Lower sample requirements can make repeated analysis more practical, helping researchers investigate treatment-response kinetics, disease progression, recovery and within-person biological variability. Rather than relying only on baseline and endpoint measurements, researchers can begin to construct a biomarker trajectory.

• Better use of precious material

Limited samples may need to support several research questions. Consuming most of a specimen in a single assay can leave insufficient material for repeat testing, orthogonal confirmation or later validation.

Sample-sparing workflows allow broad datasets to be generated while preserving material for the next stage of the biomarker programme.

• Broader biological coverage

Traditional immunoassays may require separate aliquots for individual proteins or small panels. When volume is restricted, this can force researchers to select only a few targets before the study begins.

High-multiplex approaches allow many biomarkers to be measured from the same aliquot, supporting pathway-level analysis without proportionally increasing sample consumption.

Examples of biofluids analysed in Altheome’s low-volume workflows

The most appropriate biofluid depends on the biological question, expected target abundance and intended use of the results.

• Serum

In an exercise study, Altheome used paired pre- and post-exercise serum to profile approximately 249 inflammatory, vascular and metabolic proteins. The study, described in Proteomic Profiling Reveals Insights into Exercise-Induced Modulation of Cancer Cell Biology, demonstrated how broad proteomic profiling can be combined with functional analysis to investigate systemic biological responses. [Link to app note]

• Plasma and cerebrospinal fluid

Plasma and cerebrospinal fluid are supported matrices within selected Altheome neuro biomarker workflows.

Plasma offers a more accessible option for investigating neurological biomarkers in larger or longitudinal studies, while CSF provides a biofluid more closely linked to central nervous system biology. These matrices can support high-sensitivity profiling across neurodegeneration, neuroinflammation, synaptic function, neuronal injury and vascular biology.

• Dermal interstitial fluid

Altheome has combined microneedle-based dermal interstitial fluid collection with NULISA profiling to investigate the local skin microenvironment.

More than 200 inflammation-associated proteins were detected, supporting applications in inflammatory skin biology, psoriasis and atopic dermatitis research, treatment-response monitoring and cosmetic-product evaluation. Read the application note High-Resolution Inflammatory Profiling from Dermal Interstitial Fluid in the Skin Microenvironment. [Link to application note]

Together, these examples show how low-volume analysis can support both systemic and tissue-proximal biomarker research.

The analytical challenges of low-volume studies

Using less material introduces important technical considerations. When sample availability is limited, inconsistencies in handling or assay performance can have a greater effect on the final result.

Sample handling must be consistent

Processing time, storage conditions and freeze–thaw exposure can affect protein stability. These variables should be standardised before valuable study samples are analysed.

The available volume must also account for assay input, dilution, quality-control requirements and possible repeat testing.

The biological matrix matters

Plasma, serum, CSF and dermal interstitial fluid have different protein compositions and potential interfering components. These can influence antibody binding, background signal, recovery and apparent biomarker concentration.

An assay that performs well in one matrix may not perform identically in another. Matrix compatibility should therefore be assessed alongside analytical sensitivity.

Sensitivity must match the target biology

A low-volume sample contains fewer copies of a low-abundance protein. This increases the importance of assay sensitivity, background control and analytical precision.

The key question is not simply whether a platform is described as ultra-sensitive. It is whether the required biomarker can be measured reliably within its expected biological concentration range and intended matrix.

Sample use should be planned in advance

Limited material may leave little room to repeat failed samples or investigate unexpected findings.

Before analysis begins, the sample-allocation plan should account for assay input, dilution, quality control, possible reanalysis, complementary methods and future validation. This helps prevent valuable material from being consumed too early in the project.

How ultra-sensitive proteomics expands what is possible

Selected Altheome workflows offer femtogram-per-millilitre to low-picogram-per-millilitre sensitivity, alongside flexible assay formats and low sample requirements.

Depending on the study, researchers can use broad discovery panels, focused multiplex analysis, ultra-sensitive singleplex assays or custom assay development. Selected workflows require approximately 25 µL of sample input, although requirements vary by panel and matrix.

This supports several analytical routes:

·        Broad discovery: Profile proteins and pathways from a limited aliquot

·        Focused validation: Measure selected candidates efficiently

·        Single-target analysis: Prioritise sensitivity and precision

·        Custom development: Address novel biomarkers or project-specific requirements

The most appropriate approach depends on the stage of the biomarker programme. Broad profiling may be valuable when the relevant biology is not yet known, while focused analysis may be more efficient once the target list has been defined.

Making every sample count

Low-volume analysis works best when the sample, assay and study objective are considered together.

At Altheome, support can include study-design consultation, biomarker and panel selection, matrix recommendations, data generation, quality control and downstream interpretation. The analytical strategy is designed around the available sample and the question the study needs to answer—not simply around generating the largest possible dataset.

Limited sample volume no longer has to mean limited biological insight. With appropriate planning and ultra-sensitive analysis, low-volume workflows can support broad discovery, longitudinal profiling and more efficient use of precious clinical material.

Researchers planning a limited-volume or longitudinal biomarker study can speak with the Altheome scientific team to assess sample requirements, assay options and analytical feasibility.